Clinical Trial Update: Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a sequential regimen of bendamustine, obinutuzumab, zanubrutinib, and venetoclax in relapsed/refractory chronic lymphocytic le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Bendamustine (Bendamustine)
• Gazyva (Obinutuzumab)
• Venclexta (venetoclax)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphoid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING